<DOC>
	<DOC>NCT00664534</DOC>
	<brief_summary>This study is designed to look at how best to start and then gradually intensify (as needed) the insulin lispro premix regimen in type 2 diabetes patients who consume a light breakfast.</brief_summary>
	<brief_title>Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diabetes Mellitus, Type 2 have been receiving metformin plus at least one other oral antihyperglycemic medication (OAM) (sulfonylurea or Thiazolidinedione [TZD]) without insulin, for at least 90 days prior to Visit 1 glycosylated hemoglobin (HbA1c) greater than or equal to 7.0% and less than 11.0% regularly consume a light breakfast (less than 15% of total daily calorie intake) capable and willing to follow the protocol give written consent are taking a TZD whose country label does not allow in combination with insulin are taking any glucoselowering agents (other than specified in the inclusion criteria above) have a body mass index greater than 40 kg/m^2 have a history of severe hypoglycemia in past 24 weeks are pregnant or may become pregnant women who are breastfeeding have significant cardiac disease have significant renal or liver disease undergoing therapy for a malignancy contraindications to study medications have an irregular sleep/wake cycle</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>